Last reviewed · How we verify

NCT06983756

" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "

Not yet recruiting Last updated 21 May 2025
What this trial tests

trial testing Erythropoietin in Erythropoietin Resistant Anemia (EPO Resistant Anemia) in 66 participants. Not yet recruiting.

Timeline
1 June 2025
Primary endpoint
1 December 2025
1 January 2026

Quick facts

Lead sponsorFayoum University
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment66
Start date1 June 2025
Primary completion1 December 2025
Estimated completion1 January 2026

Drugs / interventions tested

Conditions studied

Sponsor

Fayoum University

Who can join

18 and older, any sex, with Erythropoietin Resistant Anemia (EPO Resistant Anemia). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of this study is to investigate the association between metabolic syndrome and erythropoietin resistance in patients with End-Stage Kidney Disease (ESKD).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Erythropoietin

Trials testing the same drug.

Other Fayoum University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06983756.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing